ICI Pakistan Limited is pleased to announce the successful amalgamation of Cirin Pharmaceuticals (Private) Limited ("Cirin") into ICI Pakistan. With effect from March 1, 2020, all assets and liabilities of Cirin stand transferred to and vest in ICI Pakistan.

Established in 1992, Cirin manufactured a range of products that included hospital / emergency care and primary care, specifically, products in pain management (including anti-inflammatories), anti-infectives, injectable steroids, cardiometabolic disorders, gastrointestinal disorders and anxiety management.

The amalgamation is in line with ICI Pakistan's growth aspirations and enables the Company to further expand its footprint in the local pharmaceutical industry. In recent years, ICI Pakistan has increased its presence in the pharmaceuticals sector by acquiring manufacturing facilities in a bid to diversify its product portfolio to offer patients a wider range of quality healthcare products and treatment options.

ICI Pakistan Chief Executive Asif Jooma stated, "Our Pharmaceuticals Business has been going from strength to strength and the amalgamation of Cirin will enable

ICI Pakistan to expand its own manufacturing base for pharmaceutical products and will further diversify its overall product portfolio. The amalgamation is another example of our commitment to Cultivating Growth and is also an affirmation of ICI Pakistan's mission to Improve Lives."

Aamer Malik, ICI Pakistan Vice President Pharmaceuticals Business, added, "Over the last few years, ICI Pakistan's Pharmaceuticals Business has witnessed a remarkable transformation to deliver sustainable, competitive and profitable growth. This has been achieved by leveraging best practices and forging greater synergy between its various segments and portfolios. We are committed to introducing innovative products and providing the highest quality of healthcare to customers across Pakistan."-PR